Antibody Information

General Information of This Antibody
Antibody ID
ANI0PHFEE
Antibody Name
Anti-CLL1 mAb
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG
Antigen Name
C-C motif chemokine 1 (CCL1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CLL1-6 ADC [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 3.10% (Day 11) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 17.24% (Day 11) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 10 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 34.80% (Day 6) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing EOL-1 AML xenografts, each conjugate (in 10 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
CLL1-5 ADC [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 27.70% (Day 6) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing EOL-1 AML xenografts, each conjugate (in 0.5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 48.81% (Day 10) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 0.5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 61.20% (Day 6) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing EOL-1 AML xenografts, each conjugate (in 1.5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 71.08% (Day 10) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 1.5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 79.20% (Day 6) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing EOL-1 AML xenografts, each conjugate (in 5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.20% (Day 6) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing EOL-1 AML xenografts, each conjugate (in 10 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 93.89% (Day 10) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 5 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 10) High CCL1 expression (CCL1 +++)
Method Description
Single intravenous (IV) administration of the CLL1-5 ADC to mice bearing HL-60 AML xenografts, each conjugate (in 10 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model HL-60 CDX model
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
References
Ref 1 Antibody Conjugation of a Chimeric BET Degrader Enables in?vivo Activity. ChemMedChem. 2020 Jan 7;15(1):17-25. doi: 10.1002/cmdc.201900497. Epub 2019 Nov 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.